The complexity of cancer chemotherapy requires that pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensation, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
NodaK., NishiwakiY., KawaharaM.; Japan Clinical Oncology Group. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med.2002; 346(2): 85–91.
2.
HannaN., BunnP.A.Jr, LangerC.. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol.2006; 24(13): 2038–2043.
3.
HongY.S., LeeH.R., ParkS.. Three-week schedule of irinotecan plus cisplatin in patients with previously untreated extensive-stage small-cell lung cancer. Br J Cancer.2006; 95(12): 1648–1652.
4.
SekineI., NokiharaH., TakedaK.. Randomised phase II trial of irinotecan plus cisplatin vs irinotecan, cisplatin plus etoposide repeated every 3 weeks in patients with extensive-disease small-cell lung cancer. Br J Cancer.2008; 98(4): 693–696.
5.
NegoroS., MasudaN., TakadaY.; CPT-11 Lung Cancer Study Group West. Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br J Cancer.2003; 88(3): 335–341.
6.
HanJ.Y., LimH.S., LeeD.H.. Randomized phase II study of two opposite administration sequences of irinotecan and cisplatin in patients with advanced nonsmall cell lung carcinoma. Cancer.2006; 106(4): 873–880.
7.
OheY., OhashiY., KubotaK.. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol.2007; 18(2): 317–323.
8.
ParkS.H., ChoiE.Y., BangS.M.. Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes. Anticancer Drugs.2005; 16(6): 621–625.
9.
ShahM.A., RamanathanR.K., IlsonD.H.. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol.2006; 24(33): 5201–5206.
10.
LeeD.H., KimH.T., HanJ.Y.. A phase II trial of modified weekly irinotecan and cisplatin for chemotherapy-naïve patients with metastatic or recurrent squamous cell carcinoma of the esophagus. Cancer Chemother Pharmacol.2008; 61(1): 83–88.
11.
MichelP., AdenisA., Di FioreF.. Induction cisplatin-irinotecan followed by concurrent cisplatin-irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial. Br J Cancer.2006; 95(6): 705–709.
12.
NCCN clinical practice guidelines—small cell lung cancer. V.1.2009. National Comprehensive Cancer Network Web site. http://www.nccn.org. Accessed September 23, 2008.
13.
NCCN clinical practice guidelines—non-small cell lung cancer. V.1.2009. National Comprehensive Cancer Network Web site. http://www.nccn.org. Accessed September 23, 2008.
14.
NCCN clinical practice guidelines—gastric cancer. V.1.2009. National Comprehensive Cancer Network Web site. http://www.nccn.org. Accessed September 23, 2008.
15.
NCCN clinical practice guidelines—esophageal cancer. V.1.2009. National Comprehensive Cancer Network Web site. http://www.nccn.org. Accessed September 23, 2008.
16.
HeskethP.J., KrisM.G., GrunbergS.M.. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol.1997; 15(1): 103–109.
17.
NCCN clinical practice guidelines—antiemesis. V.3.2008. National Comprehensive Cancer Network Web site. http://www.nccn.org. Accessed September 24, 2008.
18.
KrisM.G., HeskethP.J., SomerfieldM.R.; American Society of Clinical Oncology. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol.2006; 24(18): 2932–2947.
19.
Antiemetic guidelines.2008. Multinational Association for Supportive Care in Cancer Web site. http://www.mascc.org. Accessed September 24, 2008.
20.
GelingO., EichlerH.G.Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol.2005; 23(6): 1289–1294.
21.
TerreyJ.P., AaproM.S.The activity of granisetron in patients who had previously failed ondansetron antiemetic therapy. Eur J Clin Res.1996; 8: 281–288.
22.
CarmichaelJ., KeizerH.J., CupissolD., MilliezJ., ScheidelP., SchindlerA.E.Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs.1998; 9(5): 381–385.
23.
de WitR., de BoerA.C., vd LindenG.H., StoterG., SparreboomA., VerweijJ.Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer.2001; 85(8): 1099–1101.
24.
SmithI.E.; Granisetron Study Group. A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. J Cancer Res Clin Oncol.1993; 119(6): 350–354.
25.
SoukopM.; Granisetron Study Group. A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Support Care Cancer.1994; 2(3): 177–183.
26.
CornelisonT.L., ReedE.Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol.1993; 50(2): 147–158.
27.
KintzelP.E.Anticancer drug-induced kidney disorders. Drug Saf.2001; 24(1): 19–38.
ZanottiK.M., MarkhamM.Prevention and management of antineoplastic-induced hypersensitivity reactions. Drug Saf.2001; 24(10): 767–779.
30.
SmithT.J., KhatcheressianJ., LymanG.H.. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol.2006; 24(19): 3187–3205.
31.
NCCN clinical practice guidelines in oncology—myeloid growth factors. V.1.2008. National Comprehensive Cancer Network Web site. http://www.nccn.org. Accessed September 25, 2008.
32.
LarsonD.L.Treatment of tissue extravasation by antitumor agents. Cancer.1982; 49(9): 1796–1799.
33.
LarsonD.L.What is the appropriate management of tissue extravasation by antitumor agents?Plast Reconstr Surgery.1985; 75(3): 397–405.
34.
MullinS., BeckwithM.C., TylerL.S.Prevention and management of antineo-plastics extravasation injury. Hosp Pharm.2000; 35(1): 57–74.
35.
BensonABIII, AjaniJ.A., CatalanoR.B.. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol.2004; 22(14): 2918–2926.
36.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev.1995; 21(1): 33–64.
37.
FloydJ., MirzaI., Sachs, PerryM.C.Hepatotoxicity of chemotherapy. Semin Oncol.2006; 33(1): 50–67.
